Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003068 · ClinicalTrials.gov registry record · Phase 2
High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00003068 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 30 participants.
The verdict
NCT00003068, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose mitoxantrone, thiotepa, and cyclophosphamide plus autologous peripheral stem cell transplantation and amifostine in treating patients with primary, locally advanced, or stage IV breast cancer.
Interventions
- DRUG cyclophosphamide
- PROCEDURE peripheral blood stem cell transplantation
- DRUG thiotepa
- DRUG amifostine trihydrate
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-06 |
| Est. Completion | 2002-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003068
The ClinicalTrials.gov registry entry for NCT00003068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003068 about?
NCT00003068 is a clinical study titled "High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to st...
What is the current status of trial NCT00003068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1997-06. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00003068?
The interventions under investigation include: cyclophosphamide (DRUG), peripheral blood stem cell transplantation (PROCEDURE), thiotepa (DRUG), amifostine trihydrate (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003068?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.